专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080057257A2 Contrast Enhancement for Optical Recording 审中-公开
标题翻译：光学记录对比度增强
公开(公告)号：US20080057257A2
公开(公告)日：2008-03-06
申请号：US11255070
申请日：2005-10-20
申请人： Geoffrey Shuy , Cheng-Ji Lu , Hsin-Cheng Lai , Fang-Yu Lee , Ko-Fu Yen
发明人： Geoffrey Shuy , Cheng-Ji Lu , Hsin-Cheng Lai , Fang-Yu Lee , Ko-Fu Yen
IPC分类号： B32B3/02
CPC分类号： G11B7/24038 , G11B7/2433 , G11B7/2531 , G11B7/2534 , G11B7/2578 , G11B2007/24308 , G11B2007/2431 , G11B2007/24312 , G11B2007/2432 , G11B2007/25706 , G11B2007/2571 , G11B2007/25715 , G11B2007/25716
摘要： A recordable medium includes an inscription layer and a contrast enhancing layer. The inscription layer has at least two sub-layers that combine upon application of a write power, the inscription layer having a reflectivity R1 before application of the write power and a reflectivity R2 after application of the write power. The contrast enhancing layer does not combine with the sub-layers of the inscription layer upon application of the write power. The contrast enhancing layer and the inscription layer together have a reflectivity R3 before application of the write power and a reflectivity R4 after application of the write power, and |R4−R3|>|R2−R1|.
摘要翻译：可记录介质包括刻录层和对比度增强层。刻录层具有在施加写入功率时组合的至少两个子层，在施加写入功率之前具有反射率R 1的刻录层和在施加写入功率之后的反射率R 2。在施加写入功率时，对比度增强层不与刻录层的子层组合。在施加写入功率之前，对比度增强层和刻录层一起具有反射率R 3，并且在施加写入功率之后具有反射率R 4，并且| R 4 -R 3 |> | R 2 -R 1 |。

2. 发明申请

US20080057255A2 Contrast Inversion for Optical Recording 审中-公开
标题翻译：光学记录对比反演
公开(公告)号：US20080057255A2
公开(公告)日：2008-03-06
申请号：US11254499
申请日：2005-10-20
申请人： Geoffrey Shuy , Cheng-Ji Lu , Hsin-Cheng Lai , Fang-Yu Lee , Yu-Yang Chang
发明人： Geoffrey Shuy , Cheng-Ji Lu , Hsin-Cheng Lai , Fang-Yu Lee , Yu-Yang Chang
IPC分类号： B32B3/02
CPC分类号： G11B7/2437 , B32B27/08 , B32B27/365 , B32B2255/10 , B32B2255/205 , B32B2255/28 , B32B2307/204 , B32B2307/412 , B32B2307/416 , B32B2429/02 , G11B7/00455 , G11B7/24038 , G11B7/2433 , G11B7/252 , G11B7/2531 , G11B7/2534
摘要： A recordable medium includes an inscription layer and at least one contrast inverting layer. The inscription layer has at least a first sub-layer and a second sub-layer that combine upon application of a write power. The inscription layer has a reflectivity R1 with respect to a read beam before application of the write power and a reflectivity R2 after application of the write power, and R1 R4.
摘要翻译：可记录介质包括刻录层和至少一个对比反转层。刻录层至少具有在施加写入功率时组合的第一子层和第二子层。刻录层在施加写入功率之前相对于读取光束具有反射率R 1，在施加写入功率之后具有反射率R 2，并且R 1 R 4。

3. 发明申请

US20060106032A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents 失效
标题翻译：作为新型抗血管生成剂，合成N 2 - （取代的芳基甲基）-3-（取代苯基）吲唑
公开(公告)号：US20060106032A1
公开(公告)日：2006-05-18
申请号：US11274528
申请日：2005-11-15
申请人： Sheng-Chu Kuo , Li-Jiau Huang , Fang-Yu Lee , Che-Ming Teng , Mei-Ling Shih , Hua-Sin Chen
发明人： Sheng-Chu Kuo , Li-Jiau Huang , Fang-Yu Lee , Che-Ming Teng , Mei-Ling Shih , Hua-Sin Chen
IPC分类号： A61K31/519 , A61K31/506 , A61K31/4745 , A61K31/4439 , A61K31/416 , C07D487/02 , C07D403/02
CPC分类号： C07D231/56 , C07D405/06
摘要： Novel compounds of 2-(substituted arylmethyl)-3-(substituted phenyl)-2H-indazoles and 1-(substituted arylmethyl)-3-(substituted phenyl)-1H-indazoles are synthesized, and useful as anti-angiogenic agents.
摘要翻译：合成2-（取代的芳基甲基）-3-（取代的苯基）-2H-吲唑和1-（取代的芳基甲基）-3-（取代的苯基）-1H-吲唑的新型化合物，可用作抗血管生成剂。

4. 发明申请

US20050209252A1 Cancer treatment 审中-公开
标题翻译：癌症治疗
公开(公告)号：US20050209252A1
公开(公告)日：2005-09-22
申请号：US11132756
申请日：2005-05-18
申请人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
发明人： Che-Ming Teng , Sheng-Chu Kuo , Fang-Yu Lee , Shiow-Lin Pan , Jih-Hwa Guh
IPC分类号： C07D405/04 , A61K31/416 , A61K31/4162 , A61K31/4745 , A61K31/519 , A61P1/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P15/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00
CPC分类号： A61K31/416 , A61K31/4162 , A61K31/4745 , A61K31/519
摘要： This invention relates to a method for treating cancer including administrating to a subject in need thereof an effective amount of a compound of the formula: wherein, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, (CH2)mC(O)N(OR)R′, N(OR)R′, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
摘要翻译：本发明涉及一种治疗癌症的方法，包括向有需要的受试者施用有效量的下式化合物：其中A为H或Ar 1，Ar 2的每一个 R 3和R 3独立地是苯基，噻吩基，呋喃基，吡咯基，吡啶基或嘧啶基; R 1，R 2，R 3，R 4，R 5，和/或R 3中的每一个 >和R 6独立地是R，硝基，卤素，C（O）OR，C（O）SR，C（O）NRR'，（CH 2）（CH 2）m，或（CH 2）m SR，（CH 2 2）m， C（O）OR（CH 2 CH 2）m C（O）OR（CH 2），（CH 2 CH 2）m CHO，（CH 2 CH 2）m CH，或CH 2，（CH 3） C（O）N（OR）R'，N（OR）R'或R 1和R 2' 一起，R 3和R 4一起，或者R 5和R 6一起是O（CH 其中R和R'各自独立地是H或C 1〜C 6，烷基; m为0,1,2,3,4,5或6，n为0,1,2或3。

5. 发明授权

US06902746B2 Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same 失效
标题翻译：含有非甾体抗炎药的口服药物组合物及其制备方法
公开(公告)号：US06902746B2
公开(公告)日：2005-06-07
申请号：US10187899
申请日：2002-07-03
申请人： Fang-Yu Lee , Shan-Chiung Chen , Ping-Kuen Chen , Han-Chiang Kuo
发明人： Fang-Yu Lee , Shan-Chiung Chen , Ping-Kuen Chen , Han-Chiang Kuo
IPC分类号： A61K9/32 , A61K9/50 , A61K31/205 , A61K31/407 , A61K47/04 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61P29/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/48
CPC分类号： A61K31/205 , A61K9/5078
摘要： The present invention provides oral pharmaceutical compositions for acetic acid class of non-steroidal anti-inflammatory drug (NSAID), particularly ketorolac. The pharmaceutical composition contains a core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating layer. The oral pharmaceutical compositons are particularly useful for treating patients with moderate to acute pain. The present invention also provides a method for making the pharmaceutical compositions and a method for using the pharmaceutical compositions.
摘要翻译：本发明提供了用于乙酸类非甾体抗炎药（NSAID）的口服药物组合物，特别是酮咯酸。药物组合物含有核心，药物层（其包含药物，粘合剂和崩解剂），保护层和肠溶衣层。口服药物组合物特别适用于治疗中度至急性疼痛的患者。本发明还提供了制备药物组合物的方法和使用该药物组合物的方法。

6. 发明授权

US06887997B2 9H-imidazo[1,2-a]purin-9-one compounds 失效
标题翻译： 9H-咪唑并[1,2-a]嘌呤-9-酮化合物
公开(公告)号：US06887997B2
公开(公告)日：2005-05-03
申请号：US10161215
申请日：2002-05-31
申请人： Fang Yu Lee , Fang Chen Lee , Chang An Yang , Ma Wei Yong , Xu Ai Wu , Wu Qiu Ye , Xiao Xu Hua
发明人： Fang Yu Lee , Fang Chen Lee , Chang An Yang , Ma Wei Yong , Xu Ai Wu , Wu Qiu Ye , Xiao Xu Hua
IPC分类号： A61K31/505 , A61K31/519 , A61P35/00 , C07D487/14
CPC分类号： C07D487/14 , A61K31/505 , A61K31/519
摘要： Fused tri-heterocyclic compounds of formula: R1 is H or alkyl; R2 is H, alkyl, alkenyl, aryl, heteroaryl, cyclyl, or heterocyclyl; R3 and R4, independently, is H, alkyl, alkenyl, aryl, heteroaryl, cyclyl, heterocyclyl, or (CRaRb)mX(CRcRd)nY; in which X is a bond, O, S, or NRe; Y is alkoxy, aryloxy, heteroaryloxy, OC(O)Re, C(O)Re, N(ReRe′), NReC(O)Re′, S(O)2Re, or SRe; each of m and n, independently, is 1, 2, 3, 4, or 5; each of Ra, Rb, Rc, Rd, Re, and Re′, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; and R5 is H or halogen.
摘要翻译：式R 1的稠合三杂环化合物是H或烷基; R 2是H，烷基，烯基，芳基，杂芳基，环基或杂环基; R 3和R 4独立地是H，烷基，烯基，芳基，杂芳基，环基，杂环基或（CR 1） SUP>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 其中X是键，O，S或NR e; Y是烷氧基，芳氧基，杂芳氧基，OC（O）R e，C（O）R e，N（R e） C（O）R e，S（O）2 R e，C（O）或SR ; m和n各自独立地是1,2,3,4或5; R a，R b，R c，R d，R d，R e，R e，且R e'独立地为H，烷基，芳基，杂芳基，环基或杂环基; R 5是H或卤素。

7. 发明授权

US06387942B2 Method of treating disorders related to protease-activated receptors-induced cell activation 有权
标题翻译：治疗与蛋白酶激活受体诱导的细胞活化有关的疾病的方法
公开(公告)号：US06387942B2
公开(公告)日：2002-05-14
申请号：US09883742
申请日：2001-06-18
申请人： Che-Ming Teng , Sheng-Chu Kuo , Fang Yu Lee
发明人： Che-Ming Teng , Sheng-Chu Kuo , Fang Yu Lee
IPC分类号： A61K3140
CPC分类号： C07D231/56 , A61K31/415 , C07D405/04 , C07D491/04 , C07D495/04
摘要： A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.
摘要翻译：治疗由蛋白酶激活受体诱导的细胞活化相关疾病的方法。该方法包括向有需要的受试者施用具有吡唑基核心的化合物; 经由亚烷基接头的芳基与吡唑基核心的1-N键合; 在吡唑基核心的4℃和5℃熔化的第二个芳基; 和直接与吡唑基核心的3-C键合的第三个芳基。

8. 发明授权

US06168806A Orally administrable nifedipine pellet and process for the preparation thereof 失效
标题翻译：口服给药的硝苯地平丸剂及其制备方法
公开(公告)号：US06168806A
公开(公告)日：2001-01-02
申请号：US09263693
申请日：1999-03-05
申请人： Fang-Yu Lee , Shan-Chiung Chen , Han-Chiang Kuo
发明人： Fang-Yu Lee , Shan-Chiung Chen , Han-Chiang Kuo
IPC分类号： A61K916
CPC分类号： A61K31/4422 , A61K9/1676 , A61K9/5078 , Y10S514/962
摘要： The present invention relates to a fast-release as well as a prolonged release type of nifedipine pellets and the process for the preparation thereof. The fast-release type of nifedipine pellets comprises a particulate core which is covered by a nifedipine coating layer. The particulate core comprises water-soluble or water-insoluble excipient(s) and a pharmacologically acceptable carrier. The nifedipine coating layer comprises an effective amount of nifedipine dissolved in organic solvent(s). This nifedipine coating layer can further be mixed with a suspension which comprises an adhesive, an emulsifier, and a dispersant. The preferred composition of the fast-release type of nifedipine includes 20-70% of the particulate core, 3-15% of nifedipine, 1-20% of emulsifier, 1-20% of adhesive, and 1-30% of dispersant. The prolonged-release type of nifedipine pellets comprises, in addition to the particulate core and the nifedipine coating layer, a surface coating layer which is made of at lease one consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose and ethylcellulose. This surface coating layer further comprises a plasticizer which is selected from the group consisting of triethylcitrate, triacetin, and diethyl phthalate.
摘要翻译：本发明涉及快速释放和延缓释放型硝苯地平丸剂及其制备方法。硝苯地平丸剂的快速释放类型包括被硝苯地平涂层覆盖的颗粒芯。颗粒核心包括水溶性或水不溶性赋形剂和药理学上可接受的载体。硝苯地平涂层包含溶解在有机溶剂中的有效量的硝苯地平。该硝苯地平涂层可以进一步与包含粘合剂，乳化剂和分散剂的悬浮液混合。快速释放型硝苯地平的优选组成包括20-70％的颗粒核，3-15％的硝苯地平，1-20％的乳化剂，1-20％的粘合剂和1-30％的分散剂。硝苯地平丸剂的延长释放型除了颗粒状核心和硝苯地平涂层外还包含由至少由羟丙基纤维素，羟丙基甲基纤维素和乙基纤维素组成的表面涂层。该表面涂层还包含选自柠檬酸三乙酯，三醋精和邻苯二甲酸二乙酯的增塑剂。

9. 发明授权

US07514465B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents 失效
标题翻译：合成N2-（取代的芳基甲基）-3-（取代苯基）吲唑作为新的抗血管生成剂
公开(公告)号：US07514465B2
公开(公告)日：2009-04-07
申请号：US11274528
申请日：2005-11-15
申请人： Sheng-Chu Kuo , Li-Jiau Huang , Fang-Yu Lee , Che-Ming Teng , Mei-Ling Shih , Hua-Sin Chen
发明人： Sheng-Chu Kuo , Li-Jiau Huang , Fang-Yu Lee , Che-Ming Teng , Mei-Ling Shih , Hua-Sin Chen
IPC分类号： C07D231/56 , A61K31/4162
CPC分类号： C07D231/56 , C07D405/06
摘要： Novel compounds of 2-(substituted arylmethyl)-3-(substituted phenyl)-2H-indazoles and 1-(substituted arylmethyl)-3-(substituted phenyl)-1H-indazoles are synthesized, and useful as anti-angiogenic agents.
摘要翻译：合成2-（取代的芳基甲基）-3-（取代的苯基）-2H-吲唑和1-（取代的芳基甲基）-3-（取代的苯基）-1H-吲唑的新型化合物，可用作抗血管生成剂。

10. 发明授权

US07378532B2 Fused pyrazolyl compound 有权
标题翻译：融合吡唑基化合物
公开(公告)号：US07378532B2
公开(公告)日：2008-05-27
申请号：US10999139
申请日：2004-11-29
申请人： Sheng-Chu Kuo , Fang-Yu Lee , Che-Ming Teng , Li-Jiau Huang , Li-Chen Chou , Jih-Hwa Guh , Shiow-Lin Pan
发明人： Sheng-Chu Kuo , Fang-Yu Lee , Che-Ming Teng , Li-Jiau Huang , Li-Chen Chou , Jih-Hwa Guh , Shiow-Lin Pan
IPC分类号： C07D231/56 , A01N43/56
CPC分类号： C07D491/04 , C07D231/56 , C07D405/04 , C07D495/04
摘要： A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.
摘要翻译：下式的稠合吡唑基化合物：其中A，Ar 1，Ar 2，R 1，R 2， R 3，R 3和R 4如本文所定义。还公开了含有有效量的上述稠合吡唑基化合物的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式